REGENXBIO Inc.
RGNX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 39.2% | -76% | 319.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | -107.9% | 57.3% | 96.1% | 70.2% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | -$0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -176.3% | -296.3% | 13.6% | -242.1% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | $0 |
| Pre-Tax Income | -$0 | -$0 | $0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -208.3% | -331.8% | 6.8% | -241.3% |
| EPS | -1.2 | -1.38 | 0.12 | -1.01 |
| % Growth | 13% | -1,250% | 111.9% | – |
| EPS Diluted | -1.2 | -1.38 | 0.12 | -1.01 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | -151% | -262.1% | 20.9% | -177.9% |